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Bosentan  reduces  immobility  time  in  the  forced  swimming  test  and  tail  suspension  test.
Bosentan  increases  circulating  IL-6  levels  in  mice  exposed  to  forced  swimming  test.
This  is  the ﬁrst  evidence  that  endothelin  mediates  depression-like  behavior.
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a  b  s  t  r  a  c  t
Endothelins  are peptides  described  initially  as  potent  vasoactive  mediators.  Recently,  studies  reported
that  endothelins  can modulate  the production  and  release  of  cytokines  by immune  cells.  In turn,  cytokines
are involved  in  depression  disorders  and  also  in  the  effectiveness  of some  antidepressants.  Therefore,  we
investigated  the  effects  of treating  mice  with  bosentan,  a mixed  endothelin  receptor  antagonist,  in  widely
used  models  for assessing  antidepressant  activity  of compounds,  the  forced  swimming  (FST)  and  the  tail
suspension  tests  (TST).  Moreover,  the  inﬂuence  of  bosentan  treatment  on  circulating  IL-6  levels  was  also
addressed  after  FST.  The  results  show  that  bosentan  treatment  induced  a bell shaped  dose-dependentepression
ytokine
antidepressant-like  effect  with  increase  in  circulating  IL-6  levels  in  animals  exposed  to  FST.  Bosentan  also
presented  antidepressant-like  effect  in TST.  Similar  results  were  obtained  with  nortriptyline  treatment
in  the  FST  and  TST.  Possible  anxiogenic  effect  of  bosentan  was  excluded  using  the  elevated  plus  maze
test.  Therefore,  this  is the  ﬁrst  study  to demonstrate  the  antidepressant-like  activity  of  bosentan  in mice,
unveiling  a previous  unrecognized  role of endothelin  in  depression  and  its possible  relation  with  increased
circulating  IL-6  levels.. Introduction
Endothelins were ﬁrst described as 21-amino acids peptides
erived from endothelial cells with potent vasoactive properties
1]. In mammals, the endothelin family comprises 3 ligands (ET-
, ET-2 and ET-3) and 2 endothelin-receptors (endothelin ETA and
TB) [2–4]. Immune cells such as macrophages [5], monocytes and
ymphocytes [6] produce endothelin and also express endothelin
eceptors, indicating the autocrine effect of endothelin in those
ells, which is related to modulation of cytokine production [7–9].
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Cytokines are cellular mediators that drive innate and adap-
tive immune responses to various stimuli. The ability of nervous
tissue to respond to cytokines allows immediate and com-
plex adaptive peripheral [10,11] and central [12] responses
of the organism. Interleukin (IL)-1, IL-6 and tumor necro-
sis factor (TNF)- are pro-inﬂammatory cytokines that have
been related to the pathophysiology of depression. The IL-
1 and TNF- can induce depressive-like symptoms in animal
models of helplessness (or despair) like Porsolt’s forced swim-
ming test (FST) [13,14]. In contrast, the systemic administration
of IL-6 induces antidepressant activity in FST, stimulates the
hypothalamo–pituitary–adrenocortical (HPA) axis, and increases
tryptophan levels and serotonin metabolism in several brain
regions [15]. Moreover, the modulation of circulating levels of these
cytokines has proved to be necessary to reverse depressive-like
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Endothelin receptor antagonists inhibit the production of
ytokines during inﬂammation [7–9]. Therefore, we  reason that
argeting endothelin receptors could affect depressive-like behav-
or by modulating the production of cytokines. In this sense, the
ffects of bosentan, a mixed endothelin ETA/ETB receptor antago-
ist, was investigated in FST, tail suspension test (TST) and elevated
lus maze test (EPM). Moreover, we also investigated the effects of
osentan on circulating levels of IL-6 after exposure to FST. Bosen-
an was selected since it was the endothelin receptor antagonist
rototype and the ﬁrst to enter clinical use [19].
. Materials and methods
.1. Animals
Male Swiss mice of 20–25 g from Universidade Estadual de
ondrina were used in this study. Mice were maintained at the
epartment of General Psychology and Behavior Analysis of the
ame University, at least two days before the experiments with free
ccess to water and food, and temperature of 23 ◦C ± 2. A 12/12 h
ight/dark cycle was used with lights on at 6 and off at 18 h. All
ehavioral tests were made between 12–17 h. Animal care and
andling procedures were approved by Ethics Committee of the
niversidade Estadual de Londrina (OF. CIRC. CEUA N◦ 07/2011).
very effort was  made to minimize the number of animals used
nd their suffering.
.2. Protocol of treatment
Bosentan (a mixed endothelin ETA/ETB receptor antagonist,
iluted in 1% solution of xanthan gum in saline) was administered
er orally (p.o.) with the aid of a gavage needle at the doses of
.3–300 mg/kg, 1 h before FST or at the dose of 3 mg/kg 1 h before
PM and TST. The vehicle group received solution of xanthan gum
% in saline (p.o.), 1 h before the tests. Nortriptyline (15 mg/kg, i.p.,
 h) was used as control drug. All groups were of 10 mice.
.3. Forced swimming test
FST was performed as previously described [20]. Brieﬂy, mice
ere placed into a cylinder of 10 cm diameter and 30 cm height
ith water at 25 ◦C ± 1 reaching 19 cm of water column to avoid the
ail touch in bottom [20]. Sessions were recorded and the immobil-
ty time (depression-like behavior) was registered in seconds by an
xperimenter unaware of the groups. Immobility was considered
hen the animal moved just to keep his head out of the water in
he last 4 min  of the total swimming session of 6 min.
.4. Tail suspension test
The TST was used as described before [21] to corroborate the
ntidepressant activity of treatment with bosentan. Mice received
osentan (3 mg/kg, p.o.), vehicle or nortriptyline (15 mg/kg, i.p.),
 h before the TST. A short piece of adhesive tape was used to
ttach mice by the tail about 20 cm above the ﬂoor. Mice were
ecorded during 6 min  and the immobility time (depression-like
ehavior) was registered in seconds by an experimenter unaware
f the groups.
.5. Elevated plus maze
In order to discard possible anxiogenic or anxiolytic activity of
osentan, which in turn would also modulate the immobility time
n forced swimming test [22], the EPM test was used as described
efore [23]. Mice received bosentan (3 mg/kg, p.o.), vehicle or nor-
riptyline (15 mg/kg, i.p.), 1 h before the EPM test. The number ofnce Letters 560 (2014) 57– 61
entries and the time spent in the open and the enclosed arms were
recorded during the session of 5 min.
2.6. Cytokine measurement
Mice were treated with bosentan (0.3–300 mg/kg, p.o.), vehicle
or nortriptyline (15 mg/kg, i.p.), 1 h before FST. In the sham group,
the cytokine levels on blood samples were determined 6 min after
swimming for just 3 s. At the end of the test, mice were terminally
anaesthetized with 1.5% isoﬂurane (Abbott Park, IL, USA) and the
blood samples were collected in microcentrifuge tubes. The sam-
ples were centrifuged at 1300 rcf for 20 min  and the supernatant
collected. IL-6 levels were determined by ELISA using eBioscience
kits as indicated by manufacturer. The results are expressed as
picograms (pg) of IL-6 per ml  of serum (n = 10).
2.7. Statistical analysis
Since the variables were only the treatments, we used analy-
sis of variance with one criterion (One-way ANOVA) followed by
the multiple comparison Tukey’s test. Differences were considered
signiﬁcant for P < 0.05.
3. Results
3.1. Treatment with bosentan reduces depression-like behavior in
FST and TST
Treatment with bosentan showed signiﬁcant reduction of the
immobility time in the FST in a dose-dependent manner (Fig. 1A). A
bell shaped curve was observed with no antidepressant-like activ-
ity at the dose of 0.3 mg/kg of bosentan, maximal effect with the
dose of 3 mg/kg and reduction of effect with the dose of 30 mg/kg
up to no effect with the dose of 300 mg/kg of bosentan. There-
fore, the dose of 3 mg/kg was  selected for the next experiments
at Fig. 1B–D. Treatment with bosentan signiﬁcantly reduced the
immobility time in TST (Fig. 1B), but showed no signiﬁcant dif-
ference in the percentage of entries into the open arms (Fig. 1C)
or in the time spent in the open arms (Fig. 1D), neither in entries
into the closed arms in EPM (data not shown) test. Taken together,
these data suggest that bosentan reduced immobility time in FST
due to an antidepressant-like activity, exclusively. The control drug
nortriptyline at a dose selected from the literature [24] presented
antidepressant-like activity as expected (Fig. 1A and B). Curiously,
the treatment with nortriptyline showed an acute anxiolytic activ-
ity in EPM test by increasing both the percentage of entries into and
time spent in the open arms (Fig. 1C and D).
3.2. Treatment with bosentan increases IL-6 serum levels in mice
exposed to FST
Exposure to FST did not alter the serum levels of IL-6 (Fig. 2).
However, the treatment with bosentan increased IL-6 serum levels
(Fig. 2). Again, a bell shaped curve was observed with signiﬁcant
increase in IL-6 serum levels in the groups treated with bosentan
at the doses of 3 and 30 mg/kg, as well as nortriptyline group. The
doses of bosentan of 0.3 and 300 mg/kg, or vehicle did not alter
signiﬁcantly the serum levels of IL-6 (Fig. 2).
4. DiscussionThe Porsolt’s forced swimming test (FST) is the most widely used
test for assessing pharmacological antidepressant activity of com-
pounds [20]. In the present study, we used FST to investigate a
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Fig. 1. Effects of bosentan and nortriptyline in the forced swimming test, tail
suspension test and elevated plus maze test. Mice were treated with bosentan
(0.3–300 mg/kg (A) or 3 mg/kg (B–D), p.o., diluted in 1% solution of xanthan gum
in  saline), vehicle or nortriptyline (15 mg/kg, i.p.) 1 h before the tests. Immobility
time was recorded during 4 or 6 min  in forced swimming test (A) or tail suspension
test  (B), respectively. Percentage of entries into the open arm (C) and time spent




















Fig. 2. Effects of bosentan and nortriptyline on circulating IL-6 levels after forced
swimming test. Mice were treated with bosentan (0.3–300 mg/kg, p.o.), vehicle
or  nortriptyline (15 mg/kg, i.p.) 1 h before the test. Blood samples were collected
immediately after the forced swimming test session and the IL-6 serum levels were
determined by ELISA. Data represent the mean ± S.E.M. serum concentration of 10
mice per group. *P < 0.01 compared to sham group and P < 0.05 compared to vehicle
group, **P < 0.001 compared to sham group and P < 0.01 compared to vehicle group,epresent the mean ± S.E.M. of immobility time (A and B), percentage of entries in
he open arm (C) or time spent in the open arm (D) of 10 mice per group. *P < 0.05
ompared to vehicle group (One-way ANOVA followed by Tukey’s test).
ew therapeutic approach for treatment of depressive disorders
y antagonizing endothelin receptors with bosentan.
Depressive disorders have been associated with serotonergic
nd catecholaminergic neurotransmission, but also with distur-
ances of systemic and brain levels of cytokines [7,13,25,26].
espite the fact that higher levels of circulating IL-6 were found
n patients with major depressive disorder [25], several antide-
ressant treatments induce acute increase of IL-6 in the central
ervous system and in the blood [17]. This evidence suggests that
ncreased levels of IL-6 are associated with antidepressant action
f drugs. In agreement, nortriptyline, a tricyclic antidepressant
hose mechanism of action relies on increase of serotonergic and
oradrenergic neurotransmission [27], induced an increase of sys-
emic IL-6 levels at a dose with antidepressant-like activity. To our
nowledge, this is the ﬁrst reported association between antide-
ressant action and IL-6 increases due to nortriptyline treatment.
his ﬁnding can be seen as suggestive that increases in systemic#P < 0.05 compared to all other groups (One-way ANOVA followed by Tukey’s test).
IL-6 level could account for the antidepressant effect of nortripty-
line. Importantly, bosentan also increased the systemic IL-6 levels
at the doses with antidepressant-like effect in the FST and TST. Of
note, bosentan inhibits inﬂammation and inﬂammatory pain at the
dose of 100 mg/kg in experimental animals, but not at 3 mg/kg
[9,28,29]. Therefore, it is likely that the antidepressant-like and
anti-inﬂammatory/analgesic actions of bosentan are dissociated.
In fact, the antidepressant-like effect of bosentan was  associated
with increased IL-6 blood levels as for nortriptyline, which would,
eventually, result in increased inﬂammation. On the other hand,
bosentan at 100 mg/kg reduces inﬂammation and pain by reduc-
ing the production of inﬂammatory cytokines including TNF-
and IL-1 [30]. Thus, it is reasonable that low doses of bosentan
present antidepressant-like activity by increasing IL-6 levels while
it inhibits inﬂammation at higher doses by reducing cytokine pro-
duction, which is compatible with the bell shape curve observed in
this study.
Furthermore, the present data does not exclude the partic-
ipation of serotonin and noradrenaline in the antidepressant
effect of nortriptyline, but rather suggests an additional mecha-
nism of action that could, in fact, be tightly related to serotonin
and noradrenaline neurotransmission as previously described in
adipocytes [31]. In a systemic approach, for example, adrenal
glands seem to be an important source of circulating IL-6 since
adrenalectomy attenuates the stress-induced increase in levels of
this cytokine [32]. On the other hand, IL-6-induced antidepressant-
like behavior showed to be related to enhanced activity of adrenal
via HPA axis [15] as a positive feedback that maintains this adaptive
response to stress. In this line, ET-1 can inhibit adrenal gland activ-
ity [33], which also suggests a possible mechanism to explain the
modulator effect of bosentan on circulating IL-6 levels observed in
this work. Considering another pathway, antidepressants such as
imipramine can inhibit splanchnic nerve activation [34] which, in
turn, modulates the activity of adrenal gland [35]. Together, these
two convergent pathways could also explain the increased levels of
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Many cell types and tissues can be important sources of
irculating IL-6, and how much this relationship of serotonin/
oradrenaline and IL-6 is important in the case of bosentan is
nknown. In fact, there is limited direct evidence on the mecha-
isms by which bosentan or blocking ETA and ETB receptors could
nduce an increased of IL-6 blood levels. Nevertheless, four addi-
ional points might help to give an insight to understand a complex
etwork resulting in increased IL-6 production by ET-1 modulation.
irst, a decrease of ET-1 levels or expression occurred concomi-
antly with increase of IL-6 levels in some models of inﬂammation
36,37]. Second, ET-1 via ETA and ETB receptors induces an increase
f IL-6 production in a synergic manner with 8-Br-cAMP, noradren-
line and adrenaline in adipocytes. This synergy was selective to
L-6 since ET-1-induced TNF and IL-1 production was  inhibited
y 8-Br-cAMP (mimicking the intracellular signaling of noradrena-
ine and adrenaline). Furthermore, this synergy occurs at low levels
f ET-1 as expected for synergic processes [31]. In this sense, ET-
 synergizes with other cytokines such as IL-1 to induce IL-6
roduction [38]. Third, treatment with bosentan increases the cir-
ulating ET-1 levels by 2 fold in humans and 2–30 folds depending
n the animal specie by a mechanism possibly related to blockade
f endothelial ETB receptors, which have a role in the clearance
f circulating ET-1 [39]. Taking into account these three points,
t is possible that in the present experimental condition, the pre-
reatment with bosentan increased the circulating levels of ET-1
t optimal doses, e.g. doses not too high to block all receptors
nd not too low to show no effect on circulating ET-1 levels. The
ncreased levels of ET-1 without blockade of all receptors (inter-
ediary doses) together with the initial release of catecholamines
n the FST test propitiated optimal serum levels of ET-1 and cat-
cholamines to induce an increase in circulating IL-6 levels and
s a result, anti-depressive-like behavior. The forth point is that
epending on the ET-1 levels, ETA and ETB receptors may  present
omplementary or even opposing roles. For instance, ET-1 induces
TB-dependent analgesia and ETA-dependent hyperalgesia at high
oses while at low doses, ET-1 induces ETA and ETB-dependent
yperalgesia [40–42]. Therefore, the effects of ET-1 might depend
n its levels.
. Conclusion
We  reported for the ﬁrst time that bosentan, a mixed endothelin
TA/ETB receptor antagonist, induces antidepressant-like activity
ssociated with elevation of circulating IL-6 levels. Therefore, the
resent data unveil a previously unrecognized participation of
ndothelin in depression and suggests a possible mechanism of
ction.
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